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Fibroblasts comprise the largest cell population in the myocardium. In heart disease, the number of fibroblasts is
increased either by replication of the resident myocardial fibroblasts, migration and transformation of circulating
bone marrow cells, or by transformation of endothelial/epithelial cells into fibroblasts and myofibroblasts. The
primary function of fibroblasts is to produce structural proteins that comprise the extracellular matrix (ECM). This
can be a constructive process; however, hyperactivity of cardiac fibroblasts can result in excess production and
deposition of ECM proteins in the myocardium, known as fibrosis, with adverse effects on cardiac structure and
function. In addition to being the primary source of ECM proteins, fibroblasts produce a number of cytokines,
peptides, and enzymes among which matrix metalloproteinases (MMPs) and their inhibitors, tissue inhibitor of
metalloproteinases (TIMPs), directly impact the ECM turnover and homeostasis. Function of fibroblasts can also in
turn be regulated by MMPs and TIMPs. In this review article, we will focus on the function of cardiac fibroblasts in
the context of ECM formation, homeostasis and remodeling in the heart. We will discuss the origins and multiple
roles of cardiac fibroblasts in myocardial remodeling in different types of heart disease in patients and in animal
models. We will further provide an overview of what we have learned from experimental animal models and
genetically modified mice with altered expression of ECM regulatory proteins, MMPs and TIMPs.
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remodeling, Heart diseaseReview
Cardiac fibroblasts
Myocardium is comprised of a number of cell types, car-
diomyocytes, cardiofibroblasts, endothelial cells and
smooth muscle cells. Cardiac fibroblasts (CFBs) have the
highest cell population in the myocardium, accounting
for about two-thirds of the cells, while cardiomyocytes
constitute about two-thirds of the myocardial tissue vol-
ume [1], although this ratio may vary in different species
[2]. A number of excellent reviews have discussed the
contribution of the contractile proteins and the mole-
cules involved in intracellular calcium handing in cardio-
myocytes in cardiac pathologies [3-5]. In this review, we
will provide an overview of the literature on the role of
CFBs in the context of extracellular matrix (ECM)* Correspondence: z.kassiri@ualberta.ca
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reproduction in any medium, provided the orremodeling and its contribution to development and
progression of heart disease. Fibroblasts (FBs) are cells
of mesenchymal origin and are present in every tissue in
the body [2,6]. Morphologically, FBs are flat and spindle-
shaped with multiple projecting processes. In the myo-
cardium, CFBs are unique among other cell types in that
they lack a basement membrane. Although historically
FBs were considered a homogeneous cell population, it
has become increasingly clear that FBs from different
tissues have different properties and functions [2,7]. In
this review we will focus our discussion on CFBs, al-
though some of the discussed properties and functions
could also apply to FBs from other tissue sources.
A number of cell surface markers have been identified
for FBs and CFBs, but over time their specificity to
these cells has been challenged. Vimentin, a protein
that is present in the intermediate filaments of FBs, has
been the most widely used FB marker – and although
it is also expressed in other cell types such as endo-
thelial cells [8] and myoepithelial cells [9], due to. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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vimentin remains a reliable marker for identifying FBs
[10]. Discoidin domain receptor (DDR) 2 was discovered
as a specific marker for CFBs [1,2,11]. DDR1 and DDR2
are collagen receptors [12,13], a family of protein tyro-
sine kinases involved in a variety of cellular functions
such as growth, migration and differentiation [14].
DDR1 is expressed mainly in epithelial cells, whereas
DDR2 is expressed in mesenchymal cells [15]. DDR2
was detected in rat and mouse heart [16], and has been
considered to be more specific than vimentin for CFBs
since it is not expressed in cardiomyocytes or cardiac
endothelial cells [11]; however, it is also expressed on
specific bone-marrow-derived cells, fibrocytes [17], leu-
kocytes, vascular smooth muscle cells [18,19], and cor-
neal epithelial and endothelial cells [20]. Another FB
marker is fibroblast-specific protein 1, a filament-
associated calcium-binding protein in FBs [21]; however,
fibroblast-specific protein 1 has also been found to be
expressed in leukocytes and a number of cancer cells
[22].
Myofibroblasts
In response to appropriate stimuli, most commonly
myocardial injury, CFBs can differentiate into myofibro-
blasts (myoFBs), which are more mobile and contractile
with a greater synthetic ability to produce ECM proteins
[23]. MyoFBs, originally identified and named by Gab-
biani in 1971 [24], are not found in healthy myocardium
and only appear following cardiac injury [25]. Similar to
CFBs, cardiac myoFBs are nonexcitable cells, but express
a number of smooth muscle cell markers that are not
typically expressed in quiescent CFBs, such as alpha
smooth muscle actin (αSMA) [26], smooth muscle my-
osin heavy chain, vinculin, paxillin, and tensin [27]. The
internal microfilmanents in the myoFBs are connected
to the extracellular fibronectin domains via specialized
adhesion complexes called fibronexus. This allows the
myoFBs to exert a contractile force on the surrounding
ECM [28]. MyoFBs are highly responsive to chemokines
released at the site of injury. This is the main mechan-
ism that mediates migration of FBs to the site of injury.
In addition, myoFBs themselves produce and secrete a
number of cytokines (for example, IL-1α, IL-1β, IL-6,
IL-10 and TNFα), which in turn help to maintain the in-
flammatory response to injury [25].
Cardiac injury triggers CFBs to be differentiated to
myoFBs, which have a stronger ability to produce ECM
proteins. MyoFB have been demonstrated to play a key
role in reparative fibrosis in the infarcted heart [29], and
to be associated with hypertrophic fibrotic scars in vari-
ous injury models. Differentiation from FB to myoFB is
promoted by transforming growth factor beta (TGFβ),
cytokines, the ECM, and other growth factors [30,31].TGFβ induces the transdifferentiation of CFBs into
myoFBs and increases collagen expression [23], whereas
IL-1β inhibits differentiation of CFBs by preventing the
expression of αSMA and other contractile proteins in
these cells [25]. In vitro, αSMA expression levels in cul-
tured CFBs are increased by passaging, and after the
third passage CFBs are believed to become myoFBs [25]
with elevated TGFβ expression such that stimulation
with exogenous TGFβ could not further increase colla-
gen production in these cells [23]. Transformation of
CFBs to myoFBs shifts the balance in ECM turnover, in-
creasing synthesis and accumulation of fibrotic deposi-
tions that can replace the myocytes and/or interrupt the
myocyte–myocyte interactions in the myocardium lead-
ing to overall impairment of cardiac function.
Origins of cardiac fibroblasts
CFBs are derived from mesenchymal cells. During heart
development, epicardial cells formed by migration of
proepicardial cells over the embryonic heart undergo
epithelial-to-mesenchymal transformation and subse-
quently differentiate into FBs [32]. This transition is
induced primarily by periostin [33] and TGFβ [34].
However, epicardial cells do not constitute all of the FBs
in the heart. In principle, they only contribute to the FBs
in the cardiac interstitium [35] and fibrous annulus
[36,37]. The annulus is an electrically inert structure that
forms the isolating barrier between the atrial and ven-
tricular tissues necessary for normal sequential activa-
tion of the heart. The FBs in the atrioventricular valve
leaflets are primarily derived from the endocardium [38].
After the completion of embryonic development, the
epicardium-derived and endocardium-derived cells be-
come quiescent.
Injury to the heart can trigger amplification of resident
CFBs, transformation of endothelial or epithelial cells to
FBs, or recruitment of hematopoietic cells originating
from the bone marrow to the site of injury and their
transformation into CFBs and myoFBs (Figure 1). Myo-
cardial fibrosis in response to cardiac pressure overload
is a characteristic feature of this disease and has been
reported to result from proliferation of resident CFBs
[39] as well as transformation of endothelial cells to
mesenchymal cells leading to generation of CFBs and
myoFBs [40,41]. Endothelial-to-mesenchymal transform-
ation can be induced by TGFβ in a Smad-dependent
fashion during cardiac fibrosis, while bone morphogenic
protein 7 blocks this process and could serve as an anti-
fibrotic factor [40]. A very recent study has reported that
suppression of receptor kinase Tie-1, but not Tie-2, pro-
motes endothelial-to-mesenchymal transformation in
human endothelial cells [42]. In addition, Notch-
mediated epithelial-to-mesenchymal transformation has
also been reported to lead to CFB proliferation in
Figure 1 Origin of cardiac fibroblasts during development and disease. During development, epicardium-derived cells undergo epithelial–
mesenchymal transformation (EMT), while endothelial cells (from the endocardium) can undergo endothelial–mesenchymal (EndMT) and
transform to cardiac fibroblasts. Following myocardial injury, bone marrow (BM)-derived cells (monocytes, BM progenitors and fibrocytes) can be
recruited to the site of injury and transformed to cardiac fibroblasts. This can occur in addition to EMT and/or EndMT.
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Bone marrow-derived cells and circulating blood
cells such as monocytes and fibrocytes are another
source of CFBs in response to injury [6]. Monocytes
have been proposed as a potential source of CFBs in
pathological fibrosis in ischemia–reperfusion injury
through elevated monocyte chemoattractant protein-1,
which promoted the uptake of hematologic monocytes
[44], and MI [45,46]. Fibrocytes, circulating FB pro-
genitor cells, originate from the hematopoietic stem
cells in the bone marrow and display phenotypic
similarities to other leukocytes such as CD14
expressed by monocytes [47]. Following MI, bone-
marrow-derived cells were found to constitute a large
number of CFBs and myoFBs in the infarct area con-
tributing to infarct formation [45,48]. In addition,bone-marrow-derived cells were found to constitute
more than 60% of the CFBs and myoFBs in an ex-
perimental autoimmune myocarditis model [49], and
about 30% of CFBs and myoFBs in cardiac pressure
overload [40]. CCR2, a chemokine receptor that is
expressed on bone marrow cells, has been shown to
be critical in recruitment of bone marrow cells to the
heart during disease since CCR2 deficiency prevented
angiotensin-II-induced accumulation of bone-marrow-
derived FB precursors (fibrocytes) in the myocardium
and cardiac fibrosis [50]. Perivascular cells, such as
pericytes, have been shown to differentiate into
collagen-producing FBs in the kidney [51] and in the
retina in vitro [52], but the contribution of these cells
in formation of CFBs has not yet been determined
[6]. In summary, the origin of CFBs during develop-
ment is different from that during disease, which
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CFBs during development, health and disease.
Functions of cardiac fibroblasts
CFBs are involved in many aspects of cardiac functions,
such as homeostasis and remodeling of the cardiac
ECM, cell–cell communication with cardiomyocytes,
electrical activity, production of growth factors and cyto-
kines, and intercellular signaling with other CFBs, endo-
thelial or smooth muscle cells that can impact cellular
events such as angiogenesis, cell proliferation, cardio-
myocyte hypertrophy or apoptosis (Figure 2). FBs can
also be reprogrammed into different cell types, such as
pluripotent stem cells [53], myoblasts [54], neurons [55].
Recently, it has been reported that FBs can be repro-
gramed to contracting cardiac-like myocytes cells by
expressing developmental transcription factors, MEF2,
HAND2, GATA4 and TBX5 [56,57], or by treatment
with a combination of miRNAs (miRNAs 1, 133, 208
and 499) [58]. As such, CFBs are critical in maintaining
normal cardiac structure, function, biochemical and
electrical features of the heart, and CFBs also play a key
role during pathological remodeling of the heart. CFBs
are conductors with a high membrane resistance [59]
and electrically separate the atria and the ventricle, by
forming the fibrotic annulus, to ensure proper contrac-
tion of the heart [36]. CFBs are connected with cardio-
myocytes via gap junctions, particularly connexins
(Cx40, Cx43, and Cx45), which is essential in maintain-
ing an optimal electrical conduction in the heart [10,60].












Figure 2 Pluripotent cardiac fibroblasts impact different
aspects of cardiac structure and function. Cardiac fibroblasts can
produce a number of active peptides (for example, cytokines,
growth factors, peptides), extracellular matrix (ECM) proteins
(collagens, elastin, fibronectin, and so forth), and ECM-regulatory
proteins, matrix metalloproteinases (MMPs) and tissue inhibitors of
matrix metalloproteinases (TIMPs). As such, cardiac fibroblasts can
impact molecular and cellular events that collectively determine
cardiac structure and function.variety of bioactive molecules and secrete them into the
myocardial interstitium. These molecules include cyto-
kines (TNFα, interleukins and TGFβ), active peptides
(angiotensin II, endothelin 1) and growth factors [61],
which function in the myocardium in autocrine and/or
paracrine fashions. CFBs are the key cell type respon-
sible for ECM homeostasis in health and its remodeling
in heart disease. CFBs synthesize the ECM proteins
while also producing the enzymes that degrade these
proteins, and inhibitors of these enzymes. In this review,
we will focus on the function of CFBs in the context of
ECM formation, homeostasis and remodeling in differ-
ent types of heart disease.
Cardiac fibroblasts are critical in extracellular matrix
homeostasis
One of the primary functions of CFBs is maintaining the
integrity of the cardiac ECM, a network structure that in
addition to providing structural and functional integrity
to the heart, also contains a number of cytokines and
growth factors that can impact cardiac function and the
fate of cardiac cells. Cardiac ECM is critical in mediating
the mechanical connection among the cardiomyocytes,
CFBs and the blood vessels within the myocardium. The
ECM also transmits extracellular mechanical signals to
the cardiomyocytes. The ECM is mainly comprised of fi-
brillar collagen types I and III, as well as less abundant
collagen types IV, V and VI. The ECM also includes
fibronectin, laminin, elastin and fibrillin, proteoglycans
and glycoproteins. CFBs are the primary source of all of
these ECM proteins [62], which can be induced by a
number of growth factors such as platelet-derived
growth factor, basic fibroblast growth factor and TGFβ
during development and disease [63].
In addition to producing ECM proteins, CFBs also
produce ECM-regulatory proteins – matrix metallopro-
teinases (MMPs), which can degrade ECM proteins –
and their inhibitors, tissue inhibitors of metalloprotei-
nases (TIMPs). A well-controlled balance between the
function of MMPs and TIMPs is critical in maintaining
ECM homeostasis [64]. MMPs are the predominant pro-
teases responsible for degradation of the ECM proteins.
MMPs are Zn2+-activated proteases that are synthesized
as inactive zymogens (pro-MMPs), and can be activated
by removal of an amino-terminal propeptide domain
and exposure of the catalytic domain. Among the 26
MMPs cloned and characterized in vertebrates, the
MMPs so far identified to be involved in myocardial re-
modeling are as follows: MMP1, MMP3, MMP8,
MMP13, MMP2, MMP9, MMP12, MMP28 and the
membrane-type MMPs (MT1-MMP/MMP14) [65-69],
although the role of higher MMPs in the cardiovascular
system is less well explored. MMP1 degrades collagen
types I, II and III and the basement membrane proteins,
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collagen types I, II and III, while MT1-MMP can cleave
a number of ECM proteins including fibronectin,
laminin-1 and fibrillar collagen type I [70-73]. Although
classically known as gelatinases, MMP2 and MMP9 also
process a number of collagens, including collagen types
I, IV and V, while MMP2 additionally cleaves collagen
type III [74]. Rodents lack the MMP1 gene but express
MMP1a (mColA) and MMP1b (mColB) genes [75], pri-
marily in the reproductive organs but not in the heart
[76]. The proteolytic activity of MMPs is kept in check
by TIMPs, the predominant inhibitors of MMPs in the
myocardium [64]. Four TIMPs have so far been cloned
[77], among which TIMP2, TIMP3 and TIMP4 are
expressed in the healthy heart, whereas TIMP1 is
expressed at low levels in the healthy heart but its levels
rise in diseased hearts [76,78-80]. TIMPs can inhibit sev-
eral MMPs, while they each also possess unique proper-
ties [81]. Although MMPs and TIMPs are best known
for their functions in ECM homeostasis, they also pos-
sess a number of other functions and properties that
have been discussed elsewhere [64,82].
CFBs can produce a number of MMPs and TIMPs
[83-86] whereby they can impact different aspects of
ECM homeostasis and remodeling. A number of growth
factors, cytokines, and chemokines have been identified
that can regulate production of MMPs and TIMPs by
CFBs. Proinflammatory cytokines such as TNFα and IL-
1β induce transcription of a number of MMPs, TIMP1
and TIMP2 in the myocardium [87]. Brain natriuretic
peptide (BNP) has been reported to be produced by
CFBs and to induce production of MMP1, MMP2,
MMP3, MMP14 and TIMP2 [88]. Adult mouse FBs have
been reported to synthesize a number of soluble secreted
MMPs (MMP13, MMP8, MMP2, and MMP9), and two
MT-MMPs (MMP14 (MT1-MMP) and MMP16 (MT3-
MMP)) [83]. Using a range of MMP-deficient mice
(MMP13−/−, MMP8−/−, MMP2−/−, MMP9−/−, MMP14−/−
(or MT1-MMP−/−) and MMP16−/− (or MT3-MMP−/−)),
Sabeh and colleagues demonstrated that only the
membrane-anchored MMP14 is required for focal colla-
gen invasion required for FB migration through the
stroma, compared with bulk collagenolysis by the sol-
uble MMPs [89].
While CFBs are the main source of ECM regulatory
proteins, MMPs and TIMPs, these molecules can also
impact on CFB function. MT1-MMP can cleave a num-
ber of ECM proteins including fibronectin, laminin-1
and fibrillar collagen type I [70-73], and has been shown
to also trigger fibrosis by cleaving and activating the la-
tent ECM-bound TGFβ, activating the Smad pathway in
CFBs and triggering collagen production [90,91]. MMP2
and MMP9 have been shown to release the ECM-bound
latent TGFβ, thereby inducing collagen synthesis [92].Consistently, cardiac overexpression of MMP2 led to se-
vere myocardial fibrosis [93]. In quiescently cultured
human CFBs, overexpression of TIMPs using specific
adenoviruses showed that each TIMP can impact
the function of CFB differently [94]. Overexpression
of Ad-TIMP1, Ad-TIMP2, Ad-TIMP3 and Ad-TIMP4
increased αSMA levels, indicating differentiation of
CFBs into myoFBs. Ad-TIMP2 increased collagen syn-
thesis by CFBs, whereas Ad-TIMP3 increased FB apop-
tosis. These functions of TIMPs were independent from
their MMP-inhibitory function [94]. These findings col-
lectively indicate that while CFBs produce ECM proteins
and the ECM-regulatory proteins, they are in turn influ-
enced by these factors working as a self-regulating cycle.
Remodeling of myocardial extracellular matrix in heart
disease patients
Remodeling of the ECM is a key component of cardiac
remodeling that occurs in disease. Disruption of the
ECM network structure interrupts the connection be-
tween the myocardial cells and blood vessels, thereby
compromising the structural integrity and function of
the heart. On the other hand, excess production and ac-
cumulation of ECM structural proteins, or fibrosis,
results in enhanced stiffness of the myocardium and
impedes ventricular contraction and relaxation, leading
to distorted architecture and function of the heart. Ex-
cess collagen deposition and fibrosis has been clearly
linked to myocardial stiffness, diastolic and systolic dys-
function [95]. Fibrosis can be the result of hyperactivity
of existing FBs that proliferate rapidly in response to in-
jury, or recruitment and proliferation of circulating
bone-marrow-derived cells that can enter the myocar-
dium and transform into FBs and myoFBs.
Fibrillar collagen types I and III are the predominant
components of cardiac ECM. These collagens are pro-
duced as pro-collagens that are then processed into ma-
ture collagen molecules upon cleavage of their pro-
peptide domain by procollagen peptidase. Assembly and
cross-linking of mature collagen molecules gives rise to
collagen fibrils and collagen fibers. During physiological
ECM turnover or pathological ECM remodeling, colla-
gen fibers are degraded and the telopeptides in the
amino-terminals or carboxy-terminals of collagen mole-
cules are cleaved (Figure 3). The pro-peptide from the
carboxy-terminal or the amino-terminal propeptides of
collagen type I (PICP, PINP), and those of collagen type
III (PIIICP, PIIINP) are released during biosynthesis of
these collagens in a stoichiometric manner, and hence
are considered biomarkers of collagen synthesis. How-
ever, the carboxy-terminal or amino-terminal telopeptide
of collagen type I (CITP, NITP) and type III (CIIITP,
NIIITP), which are produced when these collagens are
degraded, are considered biomarkers of collagen
Figure 3 Structure of collagen molecule. Pro-collagen is comprised of two alpha-1 chains and one alpha-2 chain intertwined into a triple helix.
Pro-peptide domains at the carboxy-terminals and amino-terminals are cleaved, resulting in formation of mature collagen. When collagen is
degraded, during physiological turnover or pathological adverse remodeling, telopeptides (from the amino-terminals or carboxy-terminals) are
cleaved and released into the plasma.
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heart disease patients has provided insight into cardiac
ECM remodeling in different types of heart disease.
Different reports have been made with respect to col-
lagen turnover in hypertensive patients. Reduced serum
CITP, a marker of collagen type I degradation, was sug-
gested to explain collagen deposition and fibrosis in
hypertensive patients [97], whereas a later study showed
increased CITP as well as PICP (a marker of collagen
synthesis) in hypertensive patients with left ventricular
(LV) fibrosis and diastolic dysfunction indicating
increased overall collagen turnover in these patients
[98]. Using endomyocardial biopsies from hypertensive
patients, a direct correlation was found between serum
PICP and collagen volume fraction, while PICP levels
were also higher in patients with severe fibrosis com-
pared with those with less severe fibrosis [99]. Similarly,
serum levels of PINP correlated with diastolic dysfunc-
tion in hypertensive patients without diabetes [100], sug-
gesting that a serum marker of collagen synthesis (PICP
or PINP) could be used as a biomarker for fibrosis in
hypertensive patients. In hypertrophic cardiomyopathy,
ECM turnover is a major determinant of cardiac remod-
eling. In patients with congestive heart failure, high
serum levels of cardiac fibrosis (PIIINP and PICP) are
significantly associated with poor outcome [101].
In patients with coronary artery disease but no MI,
serum levels of PIIINP, but not PINP, correlated well
with the number of diseased vessels and severity of cor-
onary artery disease [102]. In addition, in patients with
acute myocardial infarction (AMI), elevated serum
PIIINP levels during the first few days post MI was asso-
ciated with suppressed LV function, increased LV volumeover 1-year follow-up [103], poor overall prognosis and
survival [104]. Early post-MI serum PIIINP levels have
been suggested to serve as a marker of long-term LV re-
modeling and prognosis. However, a more recent study
reported that CITP served as the most suitable prognos-
tic tool in patients with acute and chronic MI compared
with PINP, PIIINP and TIMP1 [105].
In using plasma biomarkers for ECM remodeling in
patients with heart disease, it is important to keep in
mind that collagen type I is the most abundant collagen
in the human body and is ubiquitously expressed in al-
most all organs and tissues in the body. Although colla-
gen type III shows a relatively more tissue-specific
expression pattern, it is also highly expressed in the skin,
lungs and the vasculature. Hence, development of more
cardiac-specific plasma biomarkers would provide
more accurate insight into ECM alterations in the
myocardium.
Alterations in MMPs and TIMPs in heart disease patients
Alterations in MMPs and TIMPs levels have been stud-
ied in different types of heart disease as a surrogate
measure of myocardial ECM remodeling. In patients
with end-stage dilated cardiomyopathy, analysis of LV
myocardial tissue showed decreased MMP1, increased
MMP3, MMP9, TIMP1 and TIMP2, and no changes in
MMP2 levels [106]. Picard and colleagues reported
increased MMP1 and TIMP1 mRNA levels in right sep-
tal endomyocardial biopsies from patients with dilated
cardiomyopathy that did not correlate with LV diameter,
whereas collagen volume density correlated well with LV
diameter in these patients [107]. Hypertensive patients
with cardiac hypertrophy have been reported to have
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MMP9 [108], while elevated plasma TIMP1 levels have
been reported in hypertensive patients [97] that corre-
lated with diastolic dysfunction and LV fibrosis [98].
In patients with MI and unstable angina, serum levels
of MMP2 and MMP9 (but not MMP1), TIMP1, TNFα
and IL-6 were significantly elevated compared with
healthy controls, suggesting that these MMPs, TIMP1
and proinflammatory cytokines could play an important
role in the pathophysiology of acute coronary syndrome
[109]. Measurement of temporal changes in plasma
MMPs and TIMPs levels following MI showed a rapid
and sustained increase in MMP9 and MMP8, with a
delayed increase in TIMP2 and TIMP4 levels [110].
Plasma levels of MMP2 and MMP9 were elevated in
AMI patients, but only the MMP9 levels exhibited a bi-
phasic profile that peaked within the first 12 hours and
then fell to a plateau [110]. This report is consistent with
an earlier study that reported the early peak in MMP9
levels correlated with white blood cell and neutrophil
counts after AMI, and inversely correlated with LV ejec-
tion fraction and LV end-diastolic volume during the fol-
low-up, whereas the higher plateau levels later after
AMI were associated with better LV function and LV re-
modeling [111]. However, plasma MMP9 has also been
reported to serve as a useful prognostic tool in patients
with AMI, where during the 2-year follow-up plasma
MMP9 levels (but not MMP2, TNFα, C-reactive protein,
creatine kinase or pro-BNP) were the only predictive of
late-onset congestive heart failure [112]. Overall, plasma
biomarkers and their levels can be influenced by the
type, severity and stage of disease, which should be taken
into consideration when comparing reports from differ-
ent studies.
Experimental models of heart disease and extracellular
matrix remodeling
MI results from occlusion of a coronary artery, subject-
ing the downstream myocardial tissue to hypoxia and is-
chemia. The remodeling process consists of a series of
timed molecular events that include recruitment of in-
flammatory cells, proliferation of CFBs or recruitment of
circulating bone-marrow-derived cells and their differen-
tiation to myoFBs, and formation of the fibrotic scar tis-
sue. Experimental models of myocardial ischemic injury
can be generated in different species by permanent or
temporary ligation of the left anterior descending coron-
ary artery resulting in MI or ischemia–reperfusion, re-
spectively. Ischemia–reperfusion results in greater
inflammatory cell influx and prolonged inflammatory re-
sponse compared with MI, whereas in the MI model a
greater number of CFBs are detected at the injury site,
which correlates well with greater degree of fibrosis and
ECM remodeling in the MI compared with theischemia–reperfusion model [113]. CFBs are a critical
element of myocardial repair that produce collagens,
providing the tensile strength for cardiac tissue [1]. As
such, interruption or hindrance of CFB activation will
lead to decreased tensile strength of the cardiac wall,
predisposing the cardiac chambers to dilate from the
pressure of the blood within the chamber. Although in-
hibition of fibrosis post MI in mice lacking secreted
frizzled-related proteins-2 was reported to result in
beneficial outcomes [114], a recent study showed that
inhibiting CFBs (by interrupting the wnt/β-catenin sig-
naling) prevented fibrosis, impaired the wound healing,
and accelerated cardiac dilation and dysfunction within
a few days of myocardial ischemic injury in mice [115].
This study clearly indicates that the post-MI fibrosis is
reparative, and in fact a healing process and interruption
of this process may bear unfavorable outcomes [116].
The wnt-1/β-catenin has also been identified as a key
pro-fibrotic signaling pathway in myocardial ischemia–
reperfusion injury, activating the epicardial cells to
undergo epithelial-to-mesenchymal transformation, gen-
erating FBs, triggering CFB proliferation and expression
of profibrotic genes [116]. Following myocardial ische-
mic injury, MMPs mediate a number of cellular
responses, such as inflammation and fibrosis, through
processing the ECM proteins as well as non-ECM sub-
strates. MMP-mediated degradation of the ECM gener-
ates fragments that serve as chemoattractants triggering
infiltration of inflammatory cells to the site of injury.
The infiltrating macrophages and neutrophils in turn
produce a number of MMPs, such as MMP8, MMP9
and MMP12 [117-120], which then further contribute to
the adverse remodeling.
In hypertensive heart disease, reactive myocardial fi-
brosis increases myocardial stiffness and reduces compli-
ance. Roles of MMPs and TIMPs have been indicated
in the myocardial fibrosis in a number of hyperten-
sive animal models. Deoxycorticosterone acetate salt-
hypertensive rats showed higher collagen deposition
through endothelin-1-mediated TGFβ expression [121].
This was later reported to be preceded by increased
fibronectin expression, which could contribute to ECM
cell attachment and promote collagen deposition, as well
as elevated gelatinase levels (MMP2 and MMP9) [122].
While TGFβ is well known to activate the Smad sig-
naling pathway in CFBs, thereby mediating FB activation
and collagen production, a recent study by Koitabashi
and colleagues demonstrated that the TGFβ signaling
pathway in the cardiomyocytes via TGFβ-receptor 2
plays a critical role in myocardial fibrosis following pres-
sure overload [123]. Cardiomyocyte-specific knockdown
of TGFβ-receptor 2 completely blocked myocardial fi-
brosis and LV dysfunction, activation of the Smad path-
way as well as TGFβ-activated kinase 1 and preserved
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TGFβ-receptor 1 or treatment with a TGFβ neutralizing
antibody only suppressed the Smad activity (not TGFβ-
activated kinase 1) and partially suppressed fibrosis
without improving LV function [123]. As such, TGFβ-
mediated activation of TGFβ-activated kinase 1in cardio-
myocytes was proposed to underlie the maladaptive
hypertrophy and dysfunction secondary to cardiac pres-
sure overload.
Atrial natriuretic peptide and BNP have been shown
to inhibit FB proliferation, collagen synthesis and MMP
release via activation of the cGMP pathway [124], and to
oppose the TGFβ-induced ECM protein synthesis
in vitro [125,126]. These findings are particularly inter-
esting since FBs are also an important source of natri-
uretic peptides, and as such can generate a negative
feedback loop [127]. Deletion of the major natriuretic re-
ceptor for atrial natriuretic peptide and BNP, natriuretic
peptide receptor-1 in mice (Npr1−/−), resulted in hyper-
tension, cardiac hypertrophy, congestive heart failure
and sudden death at 6 months of age [128,129]. Elevated
levels of MMP2, MMP9 and TNFα in these mice were
linked to increased production of collagen types I and
III by CFBs in a TGFβ-dependent manner, leading to
myocardial fibrosis [130]. Atrial natriuretic peptide and
BNP levels are consistently elevated in heart disease in
patients [131,132] as well as in experimental models of
heart disease [133,134], and are consistently linked to se-
verity and progression of disease [135]. Taken together,
these elevated atrial natriuretic peptide and BNP levels
in heart disease could be a protective attempt by the
myocardial tissue to limit excess fibrotic deposition, tis-
sue injury and adverse remodeling.
MMPs, TIMPs, myocardial remodeling and fibrosis
As discussed earlier, a tightly controlled balance between
the function of MMPs and TIMPs is critical in maintain-
ing the ECM integrity. A number of experimental animal
models have been developed in order to determine the
contribution of MMPs and TIMPs in ECM remodeling
in heart disease, and genetically modified mice have pro-
vided valuable tools in examining the causal role of
MMPs and TIMPs in this process.
Remodeling following myocardial infarction
Targeted deletion of MMP2 improved post-MI survival
by hindering macrophage infiltration and reducing the
rate of LV rupture [136]. MMP7 has been shown to
cleave the gap junction connexin-43, thereby promoting
an arrythmogenic response post MI. MMP7 deletion
therefore improved post-MI survival and improved myo-
cardial conduction pattern owing to preserved
connexin-43 levels [137]. MMP9 deletion provided par-
tial protection against post-MI rupture [138], whilereducing LV dilation and dysfunction [139]. Lack of indi-
vidual TIMPs influenced different aspects of cardiac
structure and function following MI. In TIMP1−/− mice,
MI led to greater LV dilation and increased LV end-
diastolic volume compared with parallel wildtype mice
[140]. In mice lacking TIMP2, MI exacerbated LV dila-
tion and reduced the ejection fraction but did not alter
the rate of LV rupture compared with WT-MI mice [78].
Lack of TIMP3 increased the rate of LV rupture, wor-
sened LV dilation and reduced ejection fraction follow-
ing MI [133], whereas TIMP4 deficiency only increased
the rate of LV rupture without affecting the LV structure
or function post MI [141]. While lack of TIMP2 and
TIMP3 exacerbated infarct expansion, the increased rate
of LV rupture in TIMP3−/− and TIMP4−/− impaired
ECM remodeling in these mice. Second harmonic gener-
ation imaging further revealed reduced density and
greater disarray of fibrillar collagens in the infarct myo-
cardium of TIMP3−/− and TIMP4−/−, consistent with the
increased rate of LV rupture in these mice [133,141].
These data indicate that while TIMP1, TIMP2 and
TIMP3 exert a global impact altering the overall struc-
ture and function of the LV myocardium, the function of
TIMP4 appears to be localized to the infarcted
myocardium.
Mice overexpressing MT1-MMP showed lower sur-
vival and ejection fraction post MI compared with paral-
lel wildtype mice, whereas these parameters were
improved in mice with reduced MT1-MMP levels
(MT1-MMP+/−) [90]. Overexpression of TIMP1 has
been shown to have beneficial effects in mouse [142]
and rat [143] models of MI. Additionally, overexpression
of TIMP2 in the peri-infarct myocardium reduced the
infarct expansion and improved LV dilation and dysfunc-
tion [144].
Fibrosis and ECM remodeling in hypertension and cardiac
pressure overload
Pressure overload exerts a mechanical stress on the ven-
tricles and can trigger cardiac hypertrophy and fibrosis.
In this model of heart disease, the excessive biomechan-
ical stress is transmitted to ECM and cell–ECM connec-
tions that can lead to adverse remodeling of the ECM,
and can further activate the intracellular signaling path-
ways leading to cardiac hypertrophy, fibrosis and cell
death. MMP2-deficient mice showed reduced myocardial
hypertrophy and fibrosis [145], while MMP9 deficiency
partially improved myocardial hypertrophy and fibrosis
following pressure overload [146]. We recently reported
that in response to cardiac pressure overload, TIMP2−/−
mice exhibit greater LV dilation and dysfunction, with
non-homogeneous ECM remodeling which was charac-
terized by areas of disrupted ECM network adjacent to
regions of fibrotic lesions [134]. Myocardial fibrosis in
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increased expression of collagen type I and/or type III,
however, but due to elevated levels of SPARC (secreted
protein acidic and rich in cysteine) and enhanced post-
translational stabilization of collagen fibers [134]. Car-
diac pressure overload in TIMP3-deficient mice led to
exacerbated LV remodeling, and dysfunction [147], and
to severe myocardial fibrosis [148]. The exacerbated LV
dilation and dysfunction in these mice was found to be
due to the combined contribution of augmented MMP-
mediated proteolytic activities and heightened the
TNFα-converting enzyme–TNFα pathway [147], while
myocardial fibrosis was found to be mediated through
an interaction between the TNFα and TGFβ pathways
that led to increased expression of fibrillar collagens
[148]. Interestingly, TIMP4 was found not to contribute
to cardiac response to mechanical stress, as TIMP4−/−
mice exhibited comparable cardiac remodeling, dysfunc-
tion and myocardial fibrosis compared with the parallel
wildtype mice [141].Conclusion
The ECM is an integral component of the myocardium,
and the factors that influence the integrity of the ECM
structure also impact cardiac structure and function.
Cardiac FBs play a central role in the physiological turn-
over of the ECM as well as its pathological remodeling.
Although cardiac FBs are often associated with cardiac
fibrosis and adverse outcomes, it is important to note
that the primary function of FBs is tissue repair (wound
healing) – which in cases such as MI is in fact beneficial,
and its interruption would have undesirable outcomes.
In addition, MMPs are traditionally known for degrading
the ECM proteins, and TIMPs to inhibit this process.
However, MMPs can also promote ECM production
(and fibrosis) by regulating the activity of FBs, and simi-
larly TIMPs can influence FB behavior and ECM pro-
duction in a MMP-independent fashion. Hence, it is
critical to understand the diverse functions of MMPs,
TIMPs and FBs towards developing effective therapies to
control harmful myocardial fibrosis.
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